
Join the IMS workshop dedicated to a groundbreaking new approach to marketing.

Prix Galien Sponsorship

Pharmaceutical Executive
Marketers and sales reps feel the brunt of faltering Procrit sales as J&J consolidates its biologics divisions.

Pharmaceutical Executive
Consumer advertising might be taking a hit in the media and Congress, but pharma was all smiles at this year's PhAME Awards as the best DTC campaigns took the spotlight

Pharmaceutical Executive
Still hoping the journal article on your drug's adverse reactions will go unnoticed? Think again. A new partnership between medical journals and physician social networking site Sermo just made chatting about drugs a lot easier.

Pharmaceutical Executive
Tracking business by indication is critical for evaluating market performance and making accurate resource allocations

Pharmaceutical Executive
How to stretch that portfolio to make ends meet

Pharmaceutical Executive
FDA is being pressured to get its act together. The agency says it needs more money and more people to get approvals out the door

Pharmaceutical Executive
A plunging currency and other economic turmoil shouldn't phase pharma, right? Yes and no

Pharmaceutical Executive
Small biotech company is creating a buzz with a diabetes drug that incorporates a component found in red wine. Pharm Exec talks to Sirtris CEO Christoph Westphal about the merger and the battle against diseases of aging.

Pharmaceutical Executive
Bill Gates and Co. officially released Office for Business Applications (OBA) for the life sciences industry. This set of tools allows software developers to build applications that seamlessly connect back-end enterprise systems with MS Office programs.

Pharmaceutical Executive
As companies make headway with Web promotions, their marketers express concerns about how best to benchmark online efforts.

Pharmaceutical Executive
Blog entries about branded drugs-both positive and negative-are turning up in online keyword searches. Should pharma be worried?


Pharmaceutical Executive
Japanese drugmaker buys the cancer-specialist biotech for a whopping $8.8 billion.

Pharmaceutical Executive
GSK, Pfizer, and Merck have jumped on the cell-phone marketing bandwagon, but most of pharma is still tiptoeing around the technology. A new report details how pharma can get consumers to text for health info.

Pharmaceutical Executive
With M&As the new R&D and sales forces getting axed, the CFO is transitioning from background player to front man. A new survey documents the changing role of the pharma controller.

Pharmaceutical Executive
While some drugmakers are being pummeled for data on their "bad" cholesterol?lowering drugs, promising Phase II stats about its "good" cholesterol?raising CETP inhibitor has Roche smiling. Can it escape the torcetrapib curse?

Pharmaceutical Executive
California's plan for full-blown ePedigree implementation by 2009 just got a reality check. The hang-up? The systems are cost more and are taking longer than expected to get up and running.

Pharmaceutical Executive
Veteran salesperson Reggie Smith of Genentech makes the case for sales force diversity

Pharmaceutical Executive
Pharma is embracing the cross-functional team. But that doesn't mean that you must blend in with the sheep. Putting your best foot forward strengthens the team...and you.

Pharmaceutical Executive
International outsourcing carries risks for marketers and regulatory challenges for FDA

Pharmaceutical Executive
The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos

Pharmaceutical Executive
When it comes to developing novel therapies from the animal kingdom, it's mostly a game of pick your poison

Pharmaceutical Executive
The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos

Pharmaceutical Executive
A new study looks at the movement of thought leaders and medical science liaisons from primarily marketing to other areas of the pharma company. Though the shift might be minor (7 percent since 2002), it might be a sign of things to come.

Pharmaceutical Executive
Now that Apple has opened its iPhone to third-party software developers, healthcare productivity programs are leading the charge. Here?s a preview of one of the frontrunners.

What will the next president really mean for US healthcare policy? PwC's Sandy Lutz reports.

Pharmaceutical Executive
The US pharma market grew just 3.8 percent last year, according to IMS Health. The big loser: lipid regulators. The winners: Biologic response modulators and monoclonal antibodies.

Pharmaceutical Executive
Pharma is still having a hard time earning the confidence of the key opinion elite, as only 56 percent claim they trust the industry.